SGLT2 Inhibition in Heart Failure: New Updates

Published: 08 February 2023

Views:
10561
Likes:
7

Views:
10561
Likes:
7
Share:

Now Playing
Part 4
Efficacy and Safety of SGLT2 Inhibitors in Black Patients
Subodh Verma

Up Next

15m 19s

Part 5 Panel Discussion
Harriette Van Spall, Nandini Gupta, Subodh Verma, John JV McMurray, Xiaowen “Wendy” Wang, Pardeep Jhund

10m 28s

Part 6 SGLT2 Inhibition in Patients With Improved EF
Orly Vardeny

13m 27s

Part 7 SGLT2 Inhibition With MRAs and ARNis
Muthiah Vaduganathan

11m 47s

Part 8 Does NT-proBNP Affect the Efficacy of SGLT2 Inhibitors?
Eileen O’Meara

20m 13s

Part 9 Does EF Still Matter in HF Management?
Scott Solomon

12m 35s

Part 10 Panel Discussion
Harriette Van Spall, Nandini Gupta, Scott Solomon, Muthiah Vaduganathan, Orly Vardeny, Eileen O’Meara

29m 31s

Part 1 Do the Kidneys Hold Clues to the HF Benefits Of SGLT2 Inhibitors? John JV McMurray

10m 53s

Part 2 SGLT2 Inhibition in the Elderly and Frail Patients Pardeep Jhund

9m 34s

Part 3 Gender Differences in Outcomes With SGLT2 Inhibitors Xiaowen “Wendy” Wang

Average (ratings)

No ratings

Your rating

Overview

This on-demand version of the live broadcast provides the latest updates on SGLT2 Inhibition in heart failure.

Dr Harriette Van Spall (McMaster University, Hamilton, CA) and Dr Nandini Gupta (Mackenzie Health, Richmond Hill, CA) chair and co-chair the programme, and are joined by an outstanding international faculty for a series of insightful presentations and discussions.

Note, the live version of this session was CME accredited; this on-demand version is not.

This programme is supported by an unrestricted educational grant from AstraZeneca.

Learning Objectives

To explore the mechanisms of cardiorenal protection with SGLT2 inhibition
To examine how the safety-efficacy relationship of SGLT2 inhibitors vary with age, frailty, gender and race
To break down how SGLT2 inhibitors can be safely and optimally combined with other heart failure pharmacotherapies
To recognise the prognostic value of NT-proBNP in SGLT2 inhibition
To assess the merit of ejection fraction in heart failure care

Target Audience

Primary Care Physicians
Endocrinologists
Nephrologists
Cardiologists
Nurses
Pharmacists
Dietitians
Diabetes Educators

More from this programme

Part 1

Do the Kidneys Hold Clues to the HF Benefits Of SGLT2 Inhibitors?

1 session
Do the Kidneys Hold Clues to the HF Benefits Of SGLT2 Inhibitors?	Watch now

Part 2

SGLT2 Inhibition in the Elderly and Frail Patients

1 session
SGLT2 Inhibition in the Elderly and Frail Patients	Watch now

Part 3

Gender Differences in Outcomes With SGLT2 Inhibitors

1 session
Gender Differences in Outcomes With SGLT2 Inhibitors	Watch now

Part 4

Efficacy and Safety of SGLT2 Inhibitors in Black Patients

1 session
Efficacy and Safety of SGLT2 Inhibitors in Black Patients	Watch now

Part 5

Panel Discussion

1 session
Panel Discussion	Watch now

Part 6

SGLT2 Inhibition in Patients With Improved EF

1 session
SGLT2 Inhibition in Patients With Improved EF	Watch now

Part 7

SGLT2 Inhibition With MRAs and ARNis

1 session
SGLT2 Inhibition With MRAs and ARNis	Watch now

Part 8

Does NT-proBNP Affect the Efficacy of SGLT2 Inhibitors?

1 session
Does NT-proBNP Affect the Efficacy of SGLT2 Inhibitors?	Watch now

Part 9

Does EF Still Matter in HF Management?

1 session
Does EF Still Matter in HF Management?	Watch now

Part 10

Panel Discussion

1 session
Panel Discussion	Watch now

Faculty Biographies

Subodh Verma

Dr Subodh Verma is a cardiac surgeon-scientist at St Michael’s Hospital and Professor in the Departments of Surgery, and Pharmacology and Toxicity at the University of Toronto. He is also the current Canada Research Chair in Cardiovascular Surgery.

Dr Verma oversees a prolific basic, translational and clinical research program. He spearheads the CARDIOLINK clinical trials platform at St Michael’s Hospital and has leadership roles in seven ongoing global heart failure trials.

View full profile